A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study
evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in
the killing of ticks after they have attached to human skin.